| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011495304 |
| P356 | DOI | 10.1038/332563A0 |
| P698 | PubMed publication ID | 2965792 |
| P5875 | ResearchGate publication ID | 20190053 |
| P2093 | author name string | Partridge LJ | |
| Winter G | |||
| Burton DR | |||
| Duncan AR | |||
| Woof JM | |||
| P2860 | cites work | Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution | Q27729251 |
| Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies | Q34251290 | ||
| Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region | Q35311738 | ||
| The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes | Q37013549 | ||
| Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor | Q38352603 | ||
| Human IgG1 and its Fc fragment bind with different affinities to the Fc receptors on the human U937, HL-60 and ML-1 cell lines | Q38520523 | ||
| Immunoglobulin G: functional sites | Q39820837 | ||
| Improved oligonucleotide site-directed mutagenesis using M13 vectors. | Q40470764 | ||
| Variations in the S-S bridges of immunoglobins G: interchain disulfide bridges of gamma G3 myeloma proteins | Q44363905 | ||
| Localisation of the monocyte-binding region on human immunoglobulin G. | Q46578458 | ||
| Variability of Interchain Binding of Immunoglobulins: Interchain Bridges of Mouse IgG1 | Q57698518 | ||
| Disulphide Bridges of Immunoglobin G1 Heavy Chains | Q59062458 | ||
| Endocytosis | Q66883082 | ||
| An IgG2a-producing variant of an IgG2b-producing mouse myeloma cell line. Structural studies on the Fc region of parent and variant heavy chains | Q67402400 | ||
| The use of anti-IgG monoclonal antibodies in mapping the monocyte receptor site on IgG | Q68986422 | ||
| Is IgM-like dislocation a common feature of antibody function? | Q85699516 | ||
| Human leukocyte IgG Fc receptors | Q85700442 | ||
| The monocyte binding domain(S) on human immunoglobulin G | Q93853544 | ||
| P433 | issue | 6164 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 563-564 | |
| P577 | publication date | 1988-04-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Localization of the binding site for the human high-affinity Fc receptor on IgG. | |
| P478 | volume | 332 |
| Q33953159 | A conformational change in the Fc precludes the binding of two Fcgamma receptor molecules to one IgG. |
| Q53645990 | A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells. |
| Q40152593 | A novel Fc gamma receptor ligand augments humoral responses by targeting antigen to Fc gamma receptors |
| Q33572691 | A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types |
| Q71012001 | Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice |
| Q47864888 | Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. |
| Q45128845 | Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies |
| Q28079016 | Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life |
| Q42835972 | Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors |
| Q27685255 | An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations |
| Q37505420 | Antibody engineering to develop new antirheumatic therapies |
| Q40912749 | Antibody engineering using Escherichia coli as host |
| Q36694805 | Biologic therapies in rheumatology: lessons learned, future directions |
| Q78177133 | Boosting therapeutic potency of antibodies by taming Fc domain functions. |
| Q35180027 | Building Antibodies from their Genes |
| Q70667222 | Building antibodies from their genes |
| Q33938158 | C1q receptors. |
| Q37597698 | Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. |
| Q47959086 | Characterization of the three immunoglobulin G subclasses of macaques |
| Q37733224 | Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? |
| Q48093407 | Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs |
| Q33653661 | Comparison of intact antibody structures and the implications for effector function. |
| Q48048096 | Complement recruitment using bispecific diabodies |
| Q81543208 | Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions |
| Q27766423 | Crystal structure of the human high-affinity IgE receptor |
| Q46215386 | Designing CD4 immunoadhesins for AIDS therapy |
| Q92940332 | DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing |
| Q46879419 | Effect of glycosylation on antibody function: implications for genetic engineering |
| Q33870167 | Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 |
| Q34424958 | Engineered antibody Fc variants with enhanced effector function |
| Q39103601 | Engineered protease-resistant antibodies with selectable cell-killing functions |
| Q67470988 | Engineering Antibodies for Therapy |
| Q36846507 | Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A. |
| Q47820029 | Engineering therapeutic monoclonal antibodies |
| Q42115042 | Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons |
| Q45272924 | Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies |
| Q45741159 | Expression of Fc(gamma)r1 (CD64) on polymorphonuclear leucocytes during progression to acquired immunodeficiency syndrome in perinatally human immunodeficiency virus-infected children |
| Q38317018 | Expression of glucosamine trisaccharides on the rat uterine surface is altered by clomiphene citrate. |
| Q55421471 | Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. |
| Q54943207 | Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey. |
| Q36954763 | Fc-gamma receptors: mediators, targets and markers of disease |
| Q34565354 | Function and heterogeneity of human Fc receptors for immunoglobulin G. |
| Q51730495 | Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. |
| Q82413093 | HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice |
| Q90212766 | Harnessing the immune system via FcγR function in immune therapy: A pathway to next-gen mAbs |
| Q46117208 | High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. |
| Q37558460 | High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains |
| Q54136124 | Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. |
| Q41022012 | Human Fc receptors for IgG. |
| Q59243333 | Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis |
| Q26779758 | Human IgG4: a structural perspective |
| Q35695770 | Human antibody effector function |
| Q28252414 | Human antibody-Fc receptor interactions illuminated by crystal structures |
| Q52184933 | Humanized antibodies as potential therapeutic drugs. |
| Q40840186 | Humanized antibodies: enhancing therapeutic utility through antibody engineering |
| Q41117025 | Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells |
| Q90386023 | Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis |
| Q28141479 | Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89 |
| Q37605135 | Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies |
| Q54638658 | Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. |
| Q47593242 | IgG Fc engineering to modulate antibody effector functions |
| Q40908616 | IgG binding sites on human Fc gamma receptors |
| Q33636882 | Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. |
| Q38344654 | Increasing the serum persistence of an IgG fragment by random mutagenesis. |
| Q34773410 | Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors |
| Q73486532 | Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required |
| Q37027146 | Isotype selection in antibody engineering |
| Q30835165 | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity |
| Q72715944 | Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor |
| Q30766668 | Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chain antibodies |
| Q37578785 | Low-affinity Fcgamma receptors, autoimmunity and infection |
| Q37624015 | Man-made antibodies |
| Q64066666 | Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function |
| Q36585819 | Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies |
| Q40602173 | Molecular basis of Fc receptor function |
| Q35110825 | Monoclonal antibody-mediated protection and neutralization of motility in experimental Proteus mirabilis infection |
| Q40454744 | Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. |
| Q35774772 | One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge |
| Q34147273 | Overview on the use of therapeutic antibodies in drug discovery |
| Q28202471 | PD-L2 is a second ligand for PD-1 and inhibits T cell activation |
| Q34674773 | PEGylated antibodies and antibody fragments for improved therapy: a review |
| Q36452621 | Potent antibody therapeutics by design |
| Q90390474 | R409K mutation prevents acid-induced aggregation of human IgG4 |
| Q36370858 | Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung |
| Q40933834 | Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities |
| Q38957490 | Regulation of antibody effector functions through IgG Fc N-glycosylation |
| Q36116253 | Regulation of antibody production mediated by Fc gamma receptors, IgG binding factors, and IgG Fc-binding autoantibodies |
| Q33672201 | Secretion of functional antibody and Fab fragment from yeast cells |
| Q53316915 | Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report. |
| Q30831891 | Solid-phase synthesis and cyclization of a large branched peptide from IgG Fc with affinity for Fc gammaRI. |
| Q37734089 | Stability of IgG isotypes in serum |
| Q57212988 | Streptococcal IgA-binding Proteins Bind in the Cα2-Cα3 Interdomain Region and Inhibit Binding of IgA to Human CD89 |
| Q38615376 | Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. |
| Q50520171 | Structural analysis of effector functions related motifs, complement activation and hemagglutinating activities in Lama glama heavy chain antibodies. |
| Q40388373 | Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. |
| Q36624176 | Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa |
| Q36362075 | Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation |
| Q61651725 | Structural motifs involved in human IgG antibody effector functions |
| Q41823952 | Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor |
| Q27625567 | Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha |
| Q74419758 | TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS |
| Q33758483 | Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice. |
| Q37334251 | Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments. |
| Q27625570 | The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex |
| Q33292180 | The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans |
| Q39920154 | The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression |
| Q38239283 | The FcγR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies |
| Q41227547 | The IgG binding site of human FcgammaRIIIB receptor involves CC' and FG loops of the membrane-proximal domain |
| Q59360845 | The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine |
| Q46276474 | The antibody loci of the domestic goat (Capra hircus). |
| Q37586901 | The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. |
| Q34453640 | The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions |
| Q37097432 | The high affinity receptor for IgE on mast cells |
| Q38615370 | The high-affinity receptor for IgG, FcγRI, of humans and non-human primates. |
| Q40998108 | The influence of the hinge region length in binding of human IgG to human Fcgamma receptors |
| Q67899868 | The nature and importance of the inter-ɛ chain disulfide bonds in human IgE |
| Q33581541 | The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications |
| Q38323488 | The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding |
| Q33609768 | The structural basis of human IgE-Fc receptor interactions |
| Q54217589 | Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. |
| Q27732153 | Three-dimensional structure of a human immunoglobulin with a hinge deletion |
| Q34506062 | Transferrin-antibody fusion proteins are effective in brain targeting |
| Q37379755 | Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge |
| Q72265732 | [Recombinant immunoglobulins] |
Search more.